Sagora Therapeutics is a Canadian biotechnology company focused on developing novel therapeutic applications for existing FDA-approved compounds in neurological and underserved patient populations.
Sagora's development strategy focuses on identifying new therapeutic uses for approved small-molecule compounds with established safety and tolerability profiles. By leveraging existing clinical data and targeting clearly defined patient populations, Sagora aims to reduce development timelines while pursuing meaningful therapeutic innovation.
Building upon compounds with existing FDA approval and known tolerability data.
Targeting specific neurological indications with unmet therapeutic need.
Repurposing strategies may allow for more streamlined development compared to traditional drug discovery models.
Sagora's lead program is focused on a neurological indication within a defined patient population where current treatment options remain limited. The program is supported by a patent-pending novel method-of-treatment strategy currently under development.
Sagora Therapeutics was founded to explore innovative therapeutic strategies in neurological medicine through intellectual property development, strategic partnerships, and repurposed compound research. The company is currently focused on advancing its lead therapeutic platform while evaluating future licensing, research, and development opportunities.
Drug repurposing strategy · Neurological indications · IP development · Business development and licensing
Sagora Therapeutics welcomes discussions with potential strategic partners, clinical collaborators, researchers, and investors aligned with advancing innovative neurological therapies.
info.hadley@gmail.com